MU School of Medicine Completes Enrollment of Volunteers for Phase 3 Study of COVID-19 Vaccine Candidate

All content available for media use.

Story Summary

The University of Missouri School of Medicine’s Clinical Research Center in collaboration with the Division of Infectious Diseases has enrolled more than 100 participants in a Phase 3 COVID-19 vaccine clinical trial in the fight against coronavirus. The clinical trial is testing the safety and effectiveness of NVX-CoV2373, developed by U.S. biotechnology company Novavax, Inc. Novavax is a biotechnology company developing next-generation vaccines for serious infectious diseases.

Please contact us with any questions or issues.

Kent Faddis
Video Content Manager
MU Health Care
Office: 573-884-0532
Cell: 573-823-9499 
faddisk@health.missouri.edu

Megan Noe
Video Content Producer
MU Health Care
Office: 573-884-0512
Cell: 309-721-9885
noemm@health.missouri.edu